Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis
Future Oncology · 2024
DOI: 10.2217/fon-2022-1256 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Future Oncology, 2024. Verfasst von Francesco Passamonti und 3 weiteren Autor:innen. Beteiligte Einrichtung: Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milano, 20…. Hauptthemen laut MEDLINE: Nitriles, Pyrimidines, Pyrazoles, Primary Myelofibrosis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb, Bristol Myers Squibb.
Abstract (Originalsprache)
Aim
Fedratinib is an oral selective JAK2 inhibitor approved in the USA for the treatment of adult patients with intermediate-2 or high-risk primary or secondary myelofibrosis (MF).
Methods
This observational study assessed adult US patients who received ruxolitinib for primary MF (Flatiron Health database: 1 January 2011-31 October 2020). Patients were stratified by post-ruxolitinib treatment (fedratinib vs non-fedratinib).
Results
Characteristics were comparable between fedratinib (n=70) and non-fedratinib (n=159) groups (median age: 71.0 vs 70.0 years; females: 55.7 vs 50.3%; median follow-up: 7.0 vs 6.0 months). Median overall survival (not reached vs 17 months) and 12 month survival (71.6 vs 53.5%) were improved with fedratinib versus the non-fedratinib therapies.
Conclusion
In MF patients who received frontline ruxolitinib, survival was improved with subsequent fedratinib versus non-fedratinib care. Real-world outcomes show that in patients with primary myelofibrosis in the US, who received frontline ruxolitinib, survival was improved with subsequent fedratinib, an oral selective JAK2 inhibitor, versus non-fedratinib care.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Dipartimento di Oncologia ed Onco-Ematologia, Università degli Studi di Milano, Milano, 20122, Italy.
- Bristol Myers Squibb, 3551 Lawrenceville, NJ 08648, USA.
- Bristol Myers Squibb, Denham, Uxbridge, UB8 1DH, UK.
ORCID-Profile: Francesco Passamonti
Förderung
- Bristol-Myers Squibb
- Bristol Myers Squibb
Zitieren
APA
Passamonti, F., Lou, Y., Chevli, M., & Abraham, P. (2024). Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis. Future Oncology. https://doi.org/10.2217/fon-2022-1256
Vancouver
Passamonti F, Lou Y, Chevli M, Abraham P. Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis. Future Oncology. 2024. doi:10.2217/fon-2022-1256
BibTeX
@article{Passamonti2024,
author = {Passamonti, Francesco and Lou, Youbei and Chevli, Manoj and Abraham, Pranav},
title = {Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis},
journal = {Future Oncology},
year = {2024},
doi = {10.2217/fon-2022-1256}
}
EUVIMED